Literature DB >> 27514313

Analysis of clinical and pathological characteristics, treatment methods, survival, and prognosis of uterine papillary serous carcinoma.

Ulas Solmaz1, Atalay Ekin1, Emre Mat1, Cenk Gezer1, Askin Dogan1, Alper Biler1, Nuri Peker2, Pinar Solmaz Hasdemir3, Muzaffer Sanci1.   

Abstract

PURPOSE: Uterine papillary serous carcinoma (UPSC) is an atypical variant of endometrial carcinoma with a poor prognosis. It is commonly associated with an increased risk of extrauterine disease. The aim of this study was to investigate clinical and pathological characteristics, therapeutic methods, and prognostic factors in women with UPSC.
METHODS: All patients who underwent surgery for UPSC at a single high-volume cancer center between January 1995 and December 2010 were retrospectively reviewed. Patients who did not undergo surgical staging and those with mixed tumor histology were excluded. Univariate and multivariate regression models were used to identify the risk factors for overall survival (OS) and progression-free survival (PFS).
RESULTS: A total of 46 patients were included, the majority of whom having stage I disease (IA, 13 [28.2%] and IB, 12 [26.7%]). Stages II, III, and IV were identified in 5 (10.9%), 8 (17.4%), and 8 (17.4%) women, respectively. Optimal cytoreduction was obtained in 67.3% of patients. Recurrences developed in 8 (17.4%) patients. Multivariate analysis confirmed that lymphovascular space invasion (LVSI) (odds ratio [OR] 26.83, p = 0.003) was the only independent prognostic factor for OS, whereas LVSI and optimal cytoreduction were found to be independent prognostic factors for PFS (OR 6.91, p = 0.013 and OR 2.69, p = 0.037, respectively). The 5-year overall survival rate was 63%.
CONCLUSIONS: Our study demonstrated that LVSI is the only independent prognostic factor for OS, whereas LVSI and optimal cytoreduction are independent prognostic factors for PFS in patients with UPSC.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27514313     DOI: 10.5301/tj.5000531

Source DB:  PubMed          Journal:  Tumori        ISSN: 0300-8916            Impact factor:   2.098


  5 in total

1.  Adjuvant Pelvic Radiation "Sandwiched" Between Paclitaxel/Carboplatin Chemotherapy in Women With Completely Resected Uterine Serous Carcinoma: Long-term Follow-up of a Prospective Phase 2 Trial.

Authors:  Marina Frimer; Eirwen M Miller; Viswanathan Shankar; Eugenia Girda; Keyur Mehta; Harriet O Smith; Dennis Y S Kuo; Gary L Goldberg; Mark H Einstein
Journal:  Int J Gynecol Cancer       Date:  2018-11       Impact factor: 3.437

2.  Clinicopathological and survival analysis of uterine papillary serous carcinoma: a single institutional review of 106 cases.

Authors:  Yao Wang; Mei Yu; Jia-Xin Yang; Dong-Yan Cao; Keng Shen; Jing-He Lang
Journal:  Cancer Manag Res       Date:  2018-10-25       Impact factor: 3.989

3.  Can morphometric analysis of the fallopian tube fimbria predict the presence of uterine papillary serous carcinoma (UPSC)?

Authors:  Amnon Amit; Edmond Sabo; Avielle Movsas; Yamit Efrat-Tamam; Ari Reiss; Emad Matanes; Geula Klorin
Journal:  PLoS One       Date:  2019-02-28       Impact factor: 3.240

4.  A 4-gene signature predicts prognosis of uterine serous carcinoma.

Authors:  Hui Chen; Lingjun Li; Ping Qin; Hanzhen Xiong; Ruichao Chen; Minfen Zhang; Qingping Jiang
Journal:  BMC Cancer       Date:  2021-02-12       Impact factor: 4.430

5.  PD-L1 Expression in Endometrial Serous Carcinoma and Its Prognostic Significance.

Authors:  Tao Zhang; Qin Liu; Yingfan Zhu; Songfa Zhang; Qiaohua Peng; Amanda Louise Strickland; Wenxin Zheng; Feng Zhou
Journal:  Cancer Manag Res       Date:  2021-12-14       Impact factor: 3.989

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.